Dosing completed in Calluna Pharma’s Phase II AURORA trial

Phase 2CAL101Positive

AI Analysis

Summary

Calluna Pharma has completed patient dosing in its Phase II AURORA trial evaluating CAL101 for idiopathic pulmonary fibrosis. The milestone marks progress toward trial completion and future data readout.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Patient dosing completed

Importance:5/10

Sentiment:

0.30

Phase 2idiopathic pulmonary fibrosisdosing completedAURORA trial

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on October 14, 2026 7:48 AM

Read Original